News for hackers. Stuff that matters.
Re:How the FDA Could Change the Way It Approves Drugs by rayiner on Thursday September 03, 2015 @05:42PM (#10167698)
This is the heart of it. People like to paint this as a regulatory problem--the FDA keeping all these potentially useful drugs off the market due to its bureaucracy. But he fact is that 85-90% of drugs that hit early Stage I clinical testing don't make it through approval. That means the science is bad at predicting what will work and what won't work, and spectacularly so. That's a science problem, not a regulatory.

People bring up the "more harm than good" issue, but they're only thinking of one kind of harm: drugs that actually hurt people. But having ineffective drugs on the market also has a cost, and it's probably the bigger one. The market for effective drugs is almost certainly not efficient given the difficulty of ascertaining efficacy and the information asymmetries involved. Thus, there is a real risk of people dying because the inefficient market selects for drugs with good marketing over ones that work.

Re:How the FDA Could Change the Way It Approves Drugs by danieltillett on Thursday September 03, 2015 @06:43PM (#10167929)
Drugs die for all sorts of reasons other than being ineffective. A major one is the cost of getting a drug approved is now so expensive that you can’t make money off it. The vast majority of diseases are effectively beyond treatment because the market for them is not large enough to support the cost of developing a new drug for them.

The other major reason for failure at Stage I/II is that the preclinical models we are using are not a good match for human disease. This means that a drug that works in a mouse model can’t ever work in humans because the mouse model does not reflect the human disease (Alzheimer's is the classic for this). We are using preclinical models we know are useless and are then surprised when the drugs found using them don’t work in humans.